Attenuation of live respiratory syncytial virus vaccines is associated with reductions in levels of nasal cytokines

Journal of Infectious Diseases

Volumn 207, Issue 11, 2013, Pages 1773-1779

  Karron, Ruth A ^a   Thumar, Bhagvanji ^a   Schappell, Elizabeth ^a   Buchholz, Ursula J ^b   Collins, Peter L ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

cytokine; live attenuated vaccine; respiratory syncytial virus

Indexed keywords

EOTAXIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; LIVE VACCINE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; INFANT; LOWER RESPIRATORY TRACT INFECTION; NOSE OBSTRUCTION; OTITIS MEDIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RHINORRHEA; TREATMENT RESPONSE; VACCINATION; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS TITRATION;

EID: 84877261585     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit089     Document Type: Article

References (27)

1. Hall CB, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009; 360:588-98.
2. Nair H, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375:1545-55.
3. Collins PL, Melero JA. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 2011; 162:80-99.
4. Collins PL, et al. Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics. Adv Virus Res 1999; 54:423-51.
5. Collins PL, Murphy BR. New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. Proc Am Thorac Soc 2005; 2:166-73.
6. Wright PF, et al. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine 2007; 25:7372-8.
7. Karron RA, et al. Evaluation of two live, cold-passaged, temperaturesensitive respiratory syncytial virus (RSV) vaccines in chimpanzees, adults, infants and children. J Infect Dis 1997; 176:1428-36.
8. Wright PF, et al. Evaluation of a live, cold-passaged, temperaturesensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000; 182:1331-42.
9. Wright PF, et al. The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J Infect Dis 2006; 193:573-81.
10. Karron RA, et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 2005; 191:1093-104.
11. Jin H, et al. Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates. Vaccine 2003; 21:3647-52.
12. Luongo C, et al. Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics. J Virol 2012; 86:10792-804.
13. Bernstein DI, et al. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. Pediatr Infect Dis J 2012; 31:109-14.
14. Graham BS, Rutigliano JA, Johnson TR. Respiratory syncytial virus immunobiology and pathogenesis. Virology 2002; 297:1-7.
15. Collins PL, Graham BS. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol 2008; 82:2040-55.
16. Lotz MT, Peebles RS Jr. Mechanisms of Respiratory Syncytial Virus Modulation of Airway Immune Responses. Curr Allergy Asthma Rep 2012; 12:380-7.
17. Rosenberg HF, Domachowske JB. Inflammatory responses to respiratory syncytial virus (RSV) infection and the development of immunomodulatory pharmacotherapeutics. Curr Med Chem 2012; 19:1424-31.
18. Mobbs KJ, et al. Cytokines in severe respiratory syncytial virus bronchiolitis. Pediatr Pulmonol 2002; 33:449-52.
19. Laham FR, et al. Differential production of inflammatory cytokines in primary infection with human metapneumovirus and with other common respiratory viruses of infancy. J Infect Dis 2004; 189:2047-56.
20. McNamara PS, et al. Pro-and anti-inflammatory responses in respiratory syncytial virus bronchiolitis. Eur Respir J 2004; 23:106-12.
21. Bennett BL, et al. Immunopathogenesis of respiratory syncytial virus bronchiolitis. J Infect Dis 2007; 195:1532-40.
22. Graham BS, et al. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest 1991; 88:1026-33.
23. Prince GA, et al. Treatment of respiratory syncytial virus bronchiolitis and pneumonia in a cotton rat model wit systemically administered monoclonal antibody (palivizumab) and glucocorticosteroid. J Infect Dis 2000; 182:1326-30.
24. Malley R, et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis 1998; 178:1555-61.
25. Assefa D, et al. Attenuated interleukin-8/leukocyte immunoresponse in preterm infants compared with term infants hospitalized with respiratory syncytial virus bronchiolitis: a pilot study. Hum Immunol 2011; 72:708-11.
26. Somers CC, et al. Effect of dexamethasone on respiratory syncytial virus-induced lung inflammation in children: results of a randomized, placebo controlled clinical trial. Pediatr Allergy Immunol 2009; 20:477-85.
27. Kristjansson S, et al. Respiratory syncytial virus and other respiratory viruses during the first 3 months of life promote a local TH2-like response. J Allergy Clin Immunol 2005; 116:805-11.